GlaxoSmithKline's injectable drug. raxibacumab, has been approved by the US Food and Drug Administration for treating inhalable anthrax. Inhalation of anthrax is seen as a major bioterrorism risk and is caused when people inhale spores of anthrax bacteria. Raxibacumab has been developed by GSK's Human Genome Sciences and is a man-made protein that works by mimicking the naturally produced antibodies and blocks the toxins produced by the anthrax bacteria ...Saturday, 15 December 2012
FDA Approves Raxibacumab for Treating Inhalable Anthrax
GlaxoSmithKline's injectable drug. raxibacumab, has been approved by the US Food and Drug Administration for treating inhalable anthrax. Inhalation of anthrax is seen as a major bioterrorism risk and is caused when people inhale spores of anthrax bacteria. Raxibacumab has been developed by GSK's Human Genome Sciences and is a man-made protein that works by mimicking the naturally produced antibodies and blocks the toxins produced by the anthrax bacteria ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment